Morphic Holding Shares Outstanding 2019-2021 | MORF

Morphic Holding shares outstanding from 2019 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Morphic Holding Annual Shares Outstanding
(Millions of Shares)
2020 31
2019 16
2018 1
Morphic Holding Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 36
2021-03-31 34
2020-12-31 31
2020-09-30 32
2020-06-30 30
2020-03-31 30
2019-12-31 16
2019-09-30 30
2019-06-30 2
2019-03-31 2
2018-12-31
2018-09-30 1
2018-06-30 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.101B $0.045B
Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57